New Edition of NABCO Breast Cancer Resource List Is Now Available

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 12
Volume 5
Issue 12

NEW YORK--The National Alliance of Breast Cancer Organizations (NABCO) has just published the 1996-1997 edition of the NABCO Breast Cancer Resource List, made possible through an educational grant from Glaxo Wellcome Inc

NEW YORK--The National Alliance of Breast Cancer Organizations(NABCO) has just published the 1996-1997 edition of the NABCOBreast Cancer Resource List, made possible through an educationalgrant from Glaxo Wellcome Inc.

At more than 75 pages, it is NABCO's most comprehensive breastcancer resource guide to date. The booklet includes educationaland resource information for both the lay public and health careprofessionals, as well as a list of 350 breast cancer supportgroups nationwide. Many of the more than 2,000 listed publications(books, brochures, and videos) are available free or at low cost.

To obtain a copy, please send a self-addressed mailing label anda $3.00 check to NABCO, 9 East 37th Street, New York, NY 10016.Please indicate if you prefer the waiting room version markedwith the legend "Display Copy."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content